Cidara Therapeutics, Inc. - CDTX
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Feb 17, 2026 | SCHEDULE 13G/A | BCLS Fund III Investments, LP | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Point72 Asset Management, L.P. | 1.4% | 450,000 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Point72 Capital Advisors, Inc. | 1.4% | 450,000 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Steven A. Cohen | 1.4% | 450,000 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Vivo Opportunity Fund Holdings, L.P. | 0.0% | 0 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Vivo Opportunity, LLC | 0.0% | 0 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Vivo Opportunity Cayman Fund, L.P. | 0.0% | 0 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Vivo Opportunity Cayman, LLC | 0.0% | 0 | View |
| Jan 30, 2026 | SCHEDULE 13G | The Vanguard Group | 6.38% | 2,007,193 | View |
| Jan 09, 2026 | SCHEDULE 13D/A | — | — | — | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.